KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:待检查 入排置信度 0.96

A phase II, randomized, double-blind study of the use of rucaparib vs. placebo maintenance therapy in metastatic and recurrent endometrial cancer.

Bradley R Corr, Ashley Haggerty, Stefan M Gysler, Sarah Taylor, Kian Behbakht, Jill Alldredge, Carolyn Lefkowits, Lindsay W Brubaker, Catherine Bouts, Lisa Marie Babayan, Lainie P Martin, James Costello, Benjamin G Bitler, Junxiao Hu, Saketh R Guntupalli

Gynecol Oncol 200 58-67

PMID40700852
PMCIDPMC12398225
DOI10.1016/j.ygyno.2025.07.008
发表日期2025-07-23
入排依据:明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
图像/No. at risk 复核:历史记录没有可审查 Figure,无法确认 KM 曲线与 No. at risk 表。
AI 判定该论文不进入自动 KM 提取:The record explicitly states this is a Phase II study.
摘要

摘要

OBJECTIVE: Rucaparib is a poly(ADP-ribose) polymerase (PARP) inhibitor with proven efficacy in multiple tumor types. The efficacy of PARP inhibition in endometrial cancer remains unclear. METHODS: We conducted a multi-institutional, double-blind, placebo-controlled, randomized phase II trial. Eligible patients had stage III, IV or recurrent endometrial cancer. We assigned patients with measurable, or non-measurable disease following completion of first- or second-line chemotherapy in a 1:1 ratio to receive oral rucaparib (600 mg twice daily) or placebo until disease progression. The primary endpoint was progression-free survival. Secondary outcomes were overall survival and safety. Exploratory outcomes evaluated response in relation to tumor molecular profiles and transcriptomic profiles. RESULTS: 79 patients were randomized, 39 received rucaparib and 40 received placebo. Median progression free survival was 28.1 months in the rucaparib arm compared to 8.7 months in the placebo group, hazard ratio 0.45; (95 % confidence interval [CI] (0.24-0.87); p = 0.02). Median overall survival was not reached in the rucaparib arm compared to 28.4 months in the placebo arm; hazard ratio 0.43 (95 % CI, 0.18-1.05). In patients treated with rucaparib, the most common grade ≥ 3 adverse events were anemia, fatigue, and neutropenia. Loss of p53 activity correlated to improved rucaparib response by transcriptomic evaluation. Traditional DNA repair homologous recombination biomarkers did not correlate with response. CONCLUSIONS: Maintenance use of rucaparib after first- or second-line chemotherapy demonstrates promising activity and warrants further evaluation in a phase III evaluation. Adverse events were aligned with previous use of rucaparib in other tumor types and no new safety signals were identified. CLINICALTRIALS: gov identifier: NCT03617679.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。